155 related articles for article (PubMed ID: 7829268)
41. Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines.
Pokrovskaja K; Ehlin-Henriksson B; Bartkova J; Bartek J; Scuderi R; Szekely L; Wiman KG; Klein G
Cell Growth Differ; 1996 Dec; 7(12):1723-32. PubMed ID: 8959341
[TBL] [Abstract][Full Text] [Related]
42. Reversion of tumorigenicity in an EBV-converted Burkitt's lymphoma line.
Klein G
Ciba Found Symp; 1989; 142():36-48; discussion 48-53. PubMed ID: 2545422
[TBL] [Abstract][Full Text] [Related]
43. Integration of Epstein Barr virus near the breakpoint of a translocation 11;19 in a Burkitt's lymphoma cell line.
Wolf J; Pawlita M; Jox A; Kohls S; Bartnitzke S; Diehl V; Bullerdiek J
Cancer Genet Cytogenet; 1993 Jun; 67(2):90-4. PubMed ID: 8392436
[TBL] [Abstract][Full Text] [Related]
44. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
[TBL] [Abstract][Full Text] [Related]
45. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
Gregory CD; Rowe M; Rickinson AB
J Gen Virol; 1990 Jul; 71 ( Pt 7)():1481-95. PubMed ID: 2165133
[TBL] [Abstract][Full Text] [Related]
46. Natural killer cell sensitivity of human lymphoid lines of B-cell origin does not correlate with tumorigenicity or with the expression of certain differentiation markers.
Torsteinsdottir S; Masucci MG; Lenoir G; Klein G; Klein E
Cell Immunol; 1984 Jul; 86(2):278-86. PubMed ID: 6329520
[TBL] [Abstract][Full Text] [Related]
47. Differential effect of IL-4 and IL-13 on CD44 expression in the Burkitt's lymphoma B cell line BL30/B95-8 and in Epstein-Barr virus (EBV) transformed human B cells: loss of IL-13 receptors on Burkitt's lymphoma B cells.
Gee K; Kozlowski M; Kryworuchko M; Diaz-Mitoma F; Kumar A
Cell Immunol; 2001 Aug; 211(2):131-42. PubMed ID: 11591117
[TBL] [Abstract][Full Text] [Related]
48. Absence of IL-6 receptor expression in fresh childhood Burkitt's lymphoma cells and induction of IL-6 receptors by Epstein-Barr virus in vitro.
Tomeczkowski J; zur Stadt U; Reiter A; Welte K; Sykora KW
Br J Haematol; 1997 May; 97(2):400-8. PubMed ID: 9163607
[TBL] [Abstract][Full Text] [Related]
49. Sensitivity to dexamethasone and absence of bcl-2 protein in Burkitt's lymphoma cell line (Black93) derived from a patient with acute tumor lysis syndrome: comparative study with other BL and non-BL lines.
Tani A; Tatsumi E; Nakamura F; Kumagai S; Kosaka Y; Sano K; Nakamura H; Amakawa R; Ohno H
Leukemia; 1996 Oct; 10(10):1592-603. PubMed ID: 8847894
[TBL] [Abstract][Full Text] [Related]
50. B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas.
Yokochi T; Holly RD; Clark EA
J Immunol; 1982 Feb; 128(2):823-7. PubMed ID: 6274961
[TBL] [Abstract][Full Text] [Related]
51. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis.
Guedez L; McMarlin AJ; Kingma DW; Bennett TA; Stetler-Stevenson M; Stetler-Stevenson WG
Am J Pathol; 2001 Apr; 158(4):1207-15. PubMed ID: 11290537
[TBL] [Abstract][Full Text] [Related]
52. In vitro cytokine production and growth inhibition of lymphoblastoid cell lines by CD4+ T cells from Epstein-Barr virus (EBV) seropositive donors.
Wilson AD; Hopkins JC; Morgan AJ
Clin Exp Immunol; 2001 Oct; 126(1):101-10. PubMed ID: 11678905
[TBL] [Abstract][Full Text] [Related]
53. Interleukin-18 expression induced by Epstein-Barr virus-infected cells.
Yao L; Setsuda J; Sgadari C; Cherney B; Tosato G
J Leukoc Biol; 2001 May; 69(5):779-84. PubMed ID: 11358987
[TBL] [Abstract][Full Text] [Related]
54. Host cell phenotype-dependent methylation patterns of Epstein-Barr virus DNA.
Minarovits J; Minarovits-Kormuta S; Ehlin-Henriksson B; Falk K; Klein G; Ernberg I
J Gen Virol; 1991 Jul; 72 ( Pt 7)():1591-9. PubMed ID: 1649897
[TBL] [Abstract][Full Text] [Related]
55. Reduced signal transduction through glucocorticoid receptor in Burkitt's lymphoma cell lines.
Sinclair AJ; Jacquemin MG; Brooks L; Shanahan F; Brimmell M; Rowe M; Farrell PJ
Virology; 1994 Mar; 199(2):339-53. PubMed ID: 8122366
[TBL] [Abstract][Full Text] [Related]
56. Promotion of IL8, IL10, TNF alpha and TNF beta production by EBV infection.
Klein SC; Kube D; Abts H; Diehl V; Tesch H
Leuk Res; 1996 Aug; 20(8):633-6. PubMed ID: 8913315
[TBL] [Abstract][Full Text] [Related]
57. CAR19/22 T cell therapy in adult refractory Burkitt's lymphoma.
Zhou X; Ge T; Li T; Huang L; Cao Y; Xiao Y; Zhen M; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Aug; 70(8):2379-2384. PubMed ID: 33459843
[TBL] [Abstract][Full Text] [Related]
58. Differential expression of nucleoskeleton- and cytoskeleton-associated proteins in Burkitt lymphoma-derived and Epstein-Barr virus-immortalized lymphoblastoid cell lines.
Szekely L; Pokrovskaja K; Klein G
Cell Growth Differ; 1997 May; 8(5):599-609. PubMed ID: 9149911
[TBL] [Abstract][Full Text] [Related]
59. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice.
Tanner J; Tosato G
J Clin Invest; 1991 Jul; 88(1):239-47. PubMed ID: 1647416
[TBL] [Abstract][Full Text] [Related]
60. Immunological aspects of B-cell derived tumors in humans and rodents.
Klein G
Princess Takamatsu Symp; 1988; 19():3-13. PubMed ID: 2855874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
